IMM-101

an intradermal formulation of a heat killed whole cell mycobacterium that is not pathogenic to humans but which is known to provoke a significant delayed hypersensitivity response

Networked: 6 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dalgleish, Angus G: 3 articles (08/2022 - 01/2016)
2.	Arif, Seema Safia: 2 articles (10/2016 - 01/2016)
3.	Bidoli, Paolo: 2 articles (10/2016 - 01/2016)
4.	Carroll, Kevin J: 2 articles (10/2016 - 01/2016)
5.	Chang, David: 2 articles (10/2016 - 01/2016)
6.	Cheeseman, Sue: 2 articles (10/2016 - 01/2016)
7.	Diaz-Beveridge, Robert: 2 articles (10/2016 - 01/2016)
8.	Fernandez-Martos, Carlos: 2 articles (10/2016 - 01/2016)
9.	Gaya, Andrew: 2 articles (10/2016 - 01/2016)
10.	Glynne-Jones, Rob: 2 articles (10/2016 - 01/2016)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 10/25/2016 - "Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer." 01/01/2016 - "Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer." 01/01/2023 - "Combination treatment with IMM-101 and SBRT was safe and feasible for non-progressive locally advanced pancreatic cancer patients after (modified)FOLFIRINOX. " 12/26/2015 - "However, immunotherapy is a rapidly advancing new treatment modality, which shows promise in many solid tumor types.​ We present a patient with metastatic pancreatic cancer who underwent a synchronous resection of the primary tumour (pancreatoduodenectomy) and metastatic site (left hepatectomy) after multimodality neoadjuvant treatment with gemcitabine, nab-paclitaxel, and immunotherapy backbone with IMM-101 (an intradermally applied immunomodulator), as well as consolidation chemoradiation. "
2.	Neoplasms (Cancer) 05/01/2012 - "IMM-101 is safe and well tolerated and there is a rationale for studying IMM-101 at a nominal 1.0-mg dose to complement conventional cytotoxic therapy for patients with advanced cancer." 12/26/2015 - "However, immunotherapy is a rapidly advancing new treatment modality, which shows promise in many solid tumor types.​ We present a patient with metastatic pancreatic cancer who underwent a synchronous resection of the primary tumour (pancreatoduodenectomy) and metastatic site (left hepatectomy) after multimodality neoadjuvant treatment with gemcitabine, nab-paclitaxel, and immunotherapy backbone with IMM-101 (an intradermally applied immunomodulator), as well as consolidation chemoradiation. "
3.	Prostatic Neoplasms (Prostate Cancer) 08/01/2022 - "The aim of the present study was to describe the use of a novel immunotherapy, called IMM-101, which is a naturally occurring, heat-killed whole cell mycobacterium, used in combination with conventional treatments in patients with prostate cancer. " 08/01/2022 - "In conclusion, IMM-101 treatment alongside an anti-inflammatory agent, such as bromelain and/or LDN, may be considered an active and safe drug combination, and is a regimen that should be considered for treating patients with prostate cancer."
4.	Melanoma (Melanoma, Malignant) 05/01/2012 - "An intra-patient placebo-controlled study evaluated the safety and tolerability of three doses, namely, 0.1 (1 mg/ml), 0.5 (5 mg/ml) and 1.0 mg (10 mg/ml) of IMM-101 in stage III or IV melanoma. " 05/01/2012 - "IMM-101 is a heat-killed innate and adaptive immune-activating mycobacterial product; a phase I study aimed to determine its safety and tolerability in individuals with melanoma. " 05/01/2012 - "An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma."
5.	Adenocarcinoma 01/01/2016 - "Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma. " 12/26/2015 - "Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101."

Related Drugs and Biologics

1.	Gemcitabine
2.	Immunologic Factors (Immunomodulators)
3.	130-nm albumin-bound paclitaxel
4.	Drug Combinations
5.	Complement System Proteins (Complement)
6.	Bromelains (Bromelain)
7.	Anti-Inflammatory Agents (Anti-Inflammatories)
8.	folfirinox

Related Therapies and Procedures

1.	Immunotherapy
2.	Neoadjuvant Therapy
3.	Pancreaticoduodenectomy
4.	Hepatectomy
5.	Induction Chemotherapy